Literature DB >> 19133244

Subthalamic neurons show increased firing to 5-HT2C receptor activation in 6-hydroxydopamine-lesioned rats.

Qiao Jun Zhang1, Xin Liu, Jian Liu, Shuang Wang, Umar Ali, Zhong Heng Wu, Tao Wang.   

Abstract

The subthalamic nucleus is innervated by 5-HT afferents from the dorsal raphe nucleus and expresses high density of 5-HT(2C) receptors. However, the role of these receptors in neuronal firing of subthalamic neurons in vivo is unknown. In the present study, we examined the changes in the firing rate and firing pattern of subthalamic neurons, and the effect of the nonselective 5-HT(2C) receptor agonist m-CPP and selective antagonist SB242084 on the neuronal firing of subthalamic neurons in normal rats, sham rats, and rats with 6-hydroxydopamine lesions of the substantia nigra pars compacta by using extracellular recording. Results showed an increase in the percentage of subthalamic neurons exhibiting burst-firing pattern with no change in firing rate during the third week after the lesion compared to normal rats. The systemic administration of m-CPP (20-320 microg/kg, i.v.) dose-dependently increased the firing rate of subthalamic neurons, and the local application of m-CPP, 4 microg, in the subthalamic nucleus also increased the firing rate of subthalamic neurons in the lesioned rats. Similarly, at the same doses, the systemic and local administration of m-CPP induced the excitatory effects on subthalamic neurons in normal and sham rats. The excitatory effect of m-CPP was reversed by the subsequent administration of SB242084 (200 microg/kg, i.v.). These results suggest that the response of subthalamic neurons to 5-HT(2C) receptor stimulation is not altered after 6-hydroxydopamine lesions of the substantia nigra pars compacta.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19133244     DOI: 10.1016/j.brainres.2008.12.034

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.

Authors:  P De Deurwaerdère; M Lagière; M Bosc; S Navailles
Journal:  Exp Brain Res       Date:  2013-04-25       Impact factor: 1.972

2.  The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.

Authors:  M Lagière; S Navailles; L Mignon; A Roumegous; M-F Chesselet; P De Deurwaerdère
Journal:  Exp Brain Res       Date:  2013-03-28       Impact factor: 1.972

3.  Role of 5-HT2C receptors in the enhancement of c-Fos expression induced by a 5-HT2B/2C inverse agonist and 5-HT 2 agonists in the rat basal ganglia.

Authors:  S Navailles; M Lagière; C Le Moine; P De Deurwaerdère
Journal:  Exp Brain Res       Date:  2013-05-17       Impact factor: 1.972

4.  Serotonin2C Receptors and the Motor Control of Oral Activity.

Authors:  Mélanie Lagière; Sylvia Navailles; Marion Bosc; Martin Guthrie; Philippe De Deurwaerdère
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

5.  Increased extracellular dopamine and 5-hydroxytryptamine levels contribute to enhanced subthalamic nucleus neural activity during exhausting exercise.

Authors:  Y Hu; X Liu; D Qiao
Journal:  Biol Sport       Date:  2015-04-24       Impact factor: 2.806

6.  Modulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration.

Authors:  A Aristieta; T Morera-Herreras; J A Ruiz-Ortega; C Miguelez; I Vidaurrazaga; A Arrue; M Zumarraga; L Ugedo
Journal:  Psychopharmacology (Berl)       Date:  2013-11-24       Impact factor: 4.530

7.  A Subset of Purposeless Oral Movements Triggered by Dopaminergic Agonists Is Modulated by 5-HT2C Receptors in Rats: Implication of the Subthalamic Nucleus.

Authors:  Mélanie Lagière; Marion Bosc; Sara Whitestone; Abdelhamid Benazzouz; Abdeslam Chagraoui; Mark J Millan; Philippe De Deurwaerdère
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.